Dry eye syndrome
Conditions
Interventions
OPT treatment group:None
Sponsors
Eye Hospital, Wenzhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Age between 18 and 80 years, with no restriction on sex; 2.OPT treatment group: Meeting the clinical diagnostic criteria for meibomian gland dysfunction (MGD): presence of dry eye–related symptoms and at least one of the following signs: (1) meibomian gland obstruction or poor meibum quality; (2) at least one eyelid margin abnormality, including irregular eyelid margin, gland orifice obstruction, vascular congestion/telangiectasia, anterior displacement of the mucocutaneous junction, etc.; Planned to receive OPT treatment and able to cooperate with SS-OCTA examinations and follow-up. 3.Healthy control group: No apparent dry eye–related complaints (e.g., dryness, foreign body sensation, burning sensation, visual fatigue, etc.), and no obvious signs of eyelid margin inflammation on slit-lamp examination; Corneal fluorescein staining negative or only mild and not meeting the diagnostic criteria for dry eye disease. 4.Provision of written informed consent;
Exclusion criteria
Exclusion criteria: 1.Presence of other ocular diseases that may significantly affect the ocular surface or anterior segment (such as acute inflammation, active infection, or severe allergic conjunctivitis), or a history of eyelid or ocular surface surgery within the past 3 months; 2.Contact lens wear within the preceding 2 weeks; 3.Recent use of systemic or topical medications that may significantly influence eyelid margin congestion or inflammation and cannot be discontinued, or planned changes in dry eye–related treatment regimens during the study period; 4.Pregnancy or lactation; 5.Photosensitivity or the presence of skin or systemic conditions unsuitable for OPT treatment, including but not limited to photosensitive dermatoses, active cutaneous malignancies, or recent excessive sun exposure or tanning; 6.nability to cooperate with examinations or inadequate SS-OCTA image quality, defined as an intra-session vessel density variation greater than 10%;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of meibomian gland function;Assessment of eyelid margin vasculature using SS-OCTA.;Evaluation of marginal eyelid morphological abnormalities; | — |
Countries
China
Contacts
Public ContactYana Fu
Eye Hospital, Wenzhou Medical University
Outcome results
None listed